Fatty Liver Disease (NAFLD/MASLD)

Table of Contents

1. What Is Fatty Liver Disease?
2. NAFLD → MASLD: The 2023 Nomenclature Change
3. The Disease Spectrum: Steatosis to Cirrhosis
4. Causes, Metabolic Drivers, and Risk Factors
5. Symptoms
6. Diagnosis: Non-Invasive Tests and Liver Biopsy
7. FIB-4 Score and Fibrosis Assessment
8. Treatment: Lifestyle Reversal and Emerging Pharmacotherapy
9. GLP-1 Agonists and Emerging Drug Data
10. Dietary Approaches
11. Complications and Long-Term Prognosis
12. Research Papers
13. Connections
14. Featured Videos

What Is Fatty Liver Disease?

Fatty liver disease refers to the accumulation of excess fat (triglycerides) within hepatocytes — the liver's main functional cells. When fat infiltrates more than 5% of liver cells and this cannot be attributed to significant alcohol consumption or other specific causes, the condition is classified as non-alcoholic fatty liver disease (NAFLD) or, under the 2023 updated nomenclature, metabolic dysfunction-associated steatotic liver disease (MASLD).

Fatty liver disease is now the most common liver condition worldwide, affecting approximately 25–30% of adults globally and up to 38% of adults in the United States. The dramatic rise in prevalence parallels the obesity epidemic — fatty liver disease is the hepatic manifestation of the metabolic syndrome (abdominal obesity, insulin resistance, dyslipidemia, and hypertension). It is projected to become the leading cause of liver transplantation in the next decade, surpassing alcohol-related liver disease and hepatitis C.

NAFLD → MASLD: The 2023 Nomenclature Change

In June 2023, a multi-society consensus of hepatology organizations (AASLD, EASL, APASL, and others) endorsed a new nomenclature framework to replace NAFLD:

• Steatotic liver disease (SLD) — the overarching term for all causes of hepatic steatosis
• Metabolic dysfunction-associated steatotic liver disease (MASLD) — replaces NAFLD; requires the presence of at least one of five cardiometabolic risk factors: BMI >25 kg/m² (or >23 in Asian populations), fasting glucose ≥100 mg/dL or T2DM, blood pressure ≥130/85 mmHg, triglycerides ≥150 mg/dL, or HDL-C <40 mg/dL (men) / <50 mg/dL (women)
• Metabolic dysfunction-associated steatohepatitis (MASH) — replaces NASH (non-alcoholic steatohepatitis); the inflammatory, progressive form of MASLD
• MetALD — a new category for patients with MASLD who also have moderate alcohol consumption (140–350 g/week in women, 210–420 g/week in men)
• Alcohol-related liver disease (ALD) — for patients with heavy alcohol use exceeding MetALD thresholds

The rationale for the change was twofold: (1) the term "non-alcoholic" defined the disease by exclusion and carried stigma; (2) linking the disease explicitly to metabolic dysfunction better reflects its pathophysiology, enables more precise patient selection for trials, and reduces stigmatization. Old literature and some clinical settings will continue using NAFLD/NASH terminology for years; understanding the mapping between old and new terms is important.

The older term MAFLD (metabolic-associated fatty liver disease), proposed in 2020 by a separate international consensus group, overlaps substantially with MASLD but uses different diagnostic criteria (any fatty liver with metabolic dysregulation, overweight, or T2DM, without requiring exclusion of significant alcohol). MAFLD and MASLD are not identical; MASLD excludes high alcohol consumers that MAFLD includes.

The Disease Spectrum: Steatosis to Cirrhosis

MASLD encompasses a spectrum of histological stages with very different prognoses:

• Simple steatosis (MASL — metabolic dysfunction-associated steatotic liver, no inflammation) — fat in hepatocytes without ballooning or fibrosis. Annual risk of progression to MASH: ~4%. Risk of progression to cirrhosis: low (<5% over 10 years). Most patients with simple steatosis do not progress.
• MASH (metabolic dysfunction-associated steatohepatitis) — steatosis plus lobular inflammation and hepatocyte ballooning (a sign of cellular stress). Affects approximately 20–30% of those with MASLD. Annual risk of progression to cirrhosis: 3–15% depending on fibrosis stage at diagnosis.
• Fibrosis (F1–F4) — scarring from chronic inflammation; the strongest predictor of liver-related and all-cause mortality. Stages: F1 = perisinusoidal or periportal fibrosis; F2 = both; F3 = bridging fibrosis; F4 = cirrhosis.
• Cirrhosis (F4) — irreversible architectural distortion; portal hypertension, ascites, esophageal varices, and hepatic encephalopathy can develop. Annual hepatocellular carcinoma (HCC) risk in MASLD cirrhosis: 1–2% per year.
• Hepatocellular carcinoma — importantly, 20–50% of MASLD-related HCC occurs in patients without established cirrhosis, unlike HCV-related HCC, which requires cirrhosis in the vast majority. This complicates HCC surveillance strategies.

Causes, Metabolic Drivers, and Risk Factors

The pathophysiology of MASLD involves a "multiple-hit" model:

1. Insulin resistance — the central defect; promotes hepatic de novo lipogenesis (liver makes fat from carbohydrates) and impairs fat oxidation. Visceral adipose tissue releases excess free fatty acids into the portal circulation.
2. Oxidative stress and mitochondrial dysfunction — excess hepatic fatty acids overwhelm beta-oxidation capacity, generating reactive oxygen species that damage hepatocytes and trigger inflammation (the "second hit").
3. Gut microbiome dysbiosis — altered gut flora in MASLD increases intestinal permeability ("leaky gut"), allowing bacterial endotoxins (LPS) to reach the liver via the portal vein, activating Kupffer cells and the innate immune response.
4. Dietary fructose — high fructose corn syrup and added sugars drive de novo lipogenesis, inflammation, and uric acid production; strongly implicated in the epidemic rise of fatty liver disease.

Risk Factors

• Obesity — prevalence of MASLD is ~50% in obese individuals; rises to 80–90% in those with morbid obesity or type 2 diabetes
• Type 2 diabetes and insulin resistance — MASLD occurs in 55–75% of T2DM patients
• Dyslipidemia — particularly hypertriglyceridemia and low HDL
• Metabolic syndrome — MASLD is considered the hepatic manifestation
• Hypothyroidism — linked to MASLD through effects on lipid metabolism and hepatic fat clearance
• Polycystic ovary syndrome (PCOS) — women with PCOS have higher MASLD rates independent of BMI, related to insulin resistance
• Ethnicity — Hispanics have the highest MASLD prevalence (~45%); Black Americans have a lower prevalence (~24%) despite higher obesity rates, suggesting genetic modifiers. PNPLA3 (I148M variant) is the most influential genetic risk factor; also TM6SF2, GCKR, and HSD17B13 variants
• Sleep apnea — intermittent hypoxia may independently promote hepatic injury

Symptoms

The vast majority of patients with MASLD have no symptoms, particularly in the early stages. This is what makes the condition so insidious — liver damage can progress silently for years to decades before causing signs of cirrhosis. When present, symptoms may include:

• Fatigue — the most common complaint; non-specific and overlaps with associated metabolic conditions
• Right upper quadrant discomfort — a dull ache or pressure; may relate to hepatic capsule stretching as the liver enlarges
• Hepatomegaly — an enlarged liver detectable on physical examination or imaging
• Incidental finding on imaging — most MASLD is discovered when an ultrasound ordered for another reason shows a bright, echogenic liver

Symptoms of advanced disease (cirrhosis) include jaundice, ascites (abdominal fluid accumulation), peripheral edema, spider angiomata, and confusion (hepatic encephalopathy). Esophageal varices can rupture and cause life-threatening GI bleeding.

Diagnosis: Non-Invasive Tests and Liver Biopsy

• Liver enzymes (AST, ALT) — often mildly elevated in MASH (ALT typically greater than AST, opposite to alcohol-related liver disease where AST:ALT ratio >2); normal LFTs do not exclude MASLD or even significant fibrosis.
• Abdominal ultrasound — the first-line imaging modality for detecting hepatic steatosis. Sensitivity ~85% for moderate-severe steatosis; detects steatosis as increased echogenicity ("bright liver"). Cannot reliably quantify steatosis below 20–30% and cannot stage fibrosis.
• Controlled attenuation parameter (CAP) — measured by FibroScan (transient elastography); quantifies hepatic steatosis using ultrasound attenuation. CAP scores correlate with histological steatosis grade (S0–S3) and can be measured simultaneously with liver stiffness.
• Transient elastography (FibroScan) — measures liver stiffness as a surrogate for fibrosis. Widely available, reproducible, and well-validated. Stiffness >12 kPa suggests advanced fibrosis; >17 kPa suggests cirrhosis. Results can be falsely elevated by inflammation, congestion, or meals.
• MRI-PDFF (proton density fat fraction) — the most accurate non-invasive method for quantifying hepatic fat content; sensitivity approaches liver biopsy. MR elastography simultaneously quantifies stiffness with high accuracy for fibrosis staging. Used in clinical trials and specialized centers.
• Blood biomarkers — ELF (enhanced liver fibrosis) test, Pro-C3, FibroTest, and others combine serum analytes to estimate fibrosis stage; used as triage tools to identify who needs further evaluation.
• Liver biopsy — remains the gold standard for diagnosis and staging of MASLD/MASH. Histology is graded using the NAFLD Activity Score (NAS) or the SAF (steatosis, activity, fibrosis) algorithm. Biopsy is indicated when non-invasive tests are discordant, when diagnosis is uncertain, when fibrosis stage critically affects management decisions, or for clinical trial enrollment. Limitations: sampling variability (~30% of the liver in tiny cores), cost, procedural risk (serious complications in ~0.1–0.5%).

FIB-4 Score and Fibrosis Assessment

The FIB-4 score is the most widely used and validated non-invasive fibrosis assessment tool in MASLD. It is calculated from four readily available laboratory values:

FIB-4 = (Age × AST) / (Platelet count × √ALT)

Interpretation (standard thresholds for MASLD):

• FIB-4 <1.30 — low risk of advanced fibrosis (F0–F1); negative predictive value ~90%. No further workup for fibrosis needed in primary care.
• FIB-4 1.30–2.67 — indeterminate; refer for additional testing (FibroScan, ELF test, or hepatology assessment).
• FIB-4 >2.67 — high risk of advanced fibrosis (F3–F4); positive predictive value ~80%. Refer to hepatology; liver biopsy may be indicated.

FIB-4 is recommended by AASLD, AGA, and ACG as the initial fibrosis triage step for all patients with suspected MASLD in primary care. It is inexpensive, requires no additional testing beyond standard chemistry panels, and accurately identifies the majority of patients who can be safely observed without specialist referral. Important limitation: FIB-4 performs less well in patients under 35 (overestimates fibrosis) and those over 65 (overestimates using standard thresholds — a higher cutoff of >3.25 is recommended in patients over 65).

Treatment: Lifestyle Reversal and Emerging Pharmacotherapy

Lifestyle Modification: The Cornerstone of Treatment

Weight loss through caloric restriction and increased physical activity remains the most effective treatment for MASLD, with dose-dependent histological benefits:

• 5–7% weight loss — reduces hepatic steatosis in most patients
• 7–10% weight loss — improves steatohepatitis (MASH) histology; reduces inflammation and ballooning
• ≥10% weight loss — achieves fibrosis regression in 45% of patients; complete MASH resolution in up to 90% when sustained

The type of caloric restriction matters less than adherence. Reduced-carbohydrate and Mediterranean diets have the most evidence for hepatic fat reduction. Exercise independently reduces hepatic fat even without weight loss (aerobic exercise particularly effective; resistance training also beneficial); 150–300 minutes of moderate-intensity aerobic exercise weekly is recommended.

Bariatric Surgery

For patients with severe obesity (BMI >35) and MASLD, bariatric surgery achieves the most consistent and durable weight loss and MASLD improvement. Gastric bypass (Roux-en-Y) and sleeve gastrectomy both improve MASH histology and can reverse fibrosis. A systematic review found MASH resolution in 85% and fibrosis improvement in 34% after bariatric surgery. Contraindicated in decompensated cirrhosis; requires careful risk-benefit assessment in compensated cirrhosis.

Pharmacotherapy: Currently Approved (as of mid-2024)

• Resmetirom (Rezdiffra) — FDA-approved March 2024, the first drug specifically approved for MASH with moderate-to-advanced fibrosis (F2–F3). A selective thyroid hormone receptor beta (THR-β) agonist that reduces hepatic lipid synthesis and promotes fatty acid oxidation. In the MAESTRO-NASH trial, 26% of patients achieved MASH resolution vs. 10% placebo; 24% achieved fibrosis improvement vs. 14% placebo. Dose: 80 or 100 mg daily based on body weight. Side effects include nausea and diarrhea (usually mild). Not recommended in Child-Pugh B/C cirrhosis or with strong CYP2C8 inhibitors.

GLP-1 Agonists and Emerging Drug Data

GLP-1 receptor agonists — initially developed for type 2 diabetes and obesity — have emerged as among the most promising agents for MASLD/MASH. They promote weight loss, reduce insulin resistance, and appear to directly reduce hepatic inflammation through several mechanisms.

Key Clinical Trial Data

• Semaglutide (Ozempic/Wegovy) — the NASH trial (2021, Newsome et al., N Engl J Med) randomized 320 patients with MASH (F1–F3) to weekly semaglutide 0.4 mg vs. placebo for 72 weeks. MASH resolution occurred in 59% of semaglutide-treated patients vs. 17% placebo (P<0.001). Crucially, fibrosis improvement did not reach statistical significance (43% vs. 33%, P=0.48) — possibly due to insufficient power and short treatment duration. Weight loss was 13% vs. 1%.
• ESSENCE trial (semaglutide 2.4 mg) — phase 3 trial using the higher weight-management dose of semaglutide (2.4 mg weekly) in MASH with F2–F3 fibrosis. Results were reported in 2024 showing significantly higher rates of both MASH resolution AND fibrosis improvement compared to placebo.
• Tirzepatide (Mounjaro/Zepbound) — GIP/GLP-1 dual agonist. The SYNERGY-NASH trial (2024) showed 62% MASH resolution with tirzepatide vs. 11% placebo in F2–F3 MASH, and significant fibrosis improvement (51% vs. 30%). Results suggest superior efficacy to semaglutide, possibly due to the added GIP agonism.

GLP-1/GIP agonists are not yet FDA-approved specifically for MASH (as of mid-2024); approvals for obesity and diabetes are separate. Prescribers are increasingly using them off-label in MASLD patients who have coexisting obesity or diabetes, and insurance coverage varies. Neither semaglutide nor tirzepatide should be used in personal or family history of medullary thyroid carcinoma or MEN2.

Other Emerging Therapies

• Lanifibranor (PPAR pan-agonist) — NATIVE trial showed significant MASH resolution and fibrosis improvement; under regulatory review in Europe and US.
• Obeticholic acid (FXR agonist) — showed fibrosis benefit in the REGENERATE trial but development complicated by pruritis and lipid effects; FDA approval sought for fibrosis endpoint.
• Aldafermin (FGF19 analog), efruxifermin (FGF21 analog) — reduce hepatic lipogenesis; phase 2 trials showing promise.
• Vitamin E (alpha-tocopherol) — 800 IU daily improved MASH histology in non-diabetic patients in the PIVENS trial; modest effect, concerns about cardiovascular risk with long-term high-dose use. Still used in clinical practice for non-diabetic MASH.
• Pioglitazone — thiazolidinedione insulin sensitizer; improves MASH histology including fibrosis in patients with or without T2DM. Used clinically but limited by weight gain, bone density loss, and cardiac fluid retention risk.

Dietary Approaches

• Mediterranean diet — the best-evidenced dietary pattern for MASLD. Rich in olive oil, fish, legumes, whole grains, fruits, and vegetables. Reduces hepatic fat independent of caloric restriction; associated with slower fibrosis progression in observational studies.
• Low-carbohydrate / ketogenic diet — rapid reduction in hepatic fat (often within 2 weeks); particularly effective for patients with marked insulin resistance. Long-term adherence is challenging; efficacy for fibrosis is less studied.
• Eliminate added fructose and sugar-sweetened beverages — the single most impactful specific dietary change; fructose drives de novo lipogenesis directly. Avoid sodas, fruit juices, high-fructose corn syrup in processed foods.
• Eliminate or strictly limit alcohol — even moderate alcohol accelerates fibrosis in MASLD. The safe threshold in MASLD is not established; conservative recommendations suggest complete abstinence in patients with advanced fibrosis or MASH.
• Coffee — regular coffee consumption (2–4 cups/day) is consistently associated with lower risk of advanced fibrosis and reduced all-cause mortality in MASLD; likely mediated by polyphenols and effects on hepatic inflammation. This is observational but robust across multiple populations.
• Omega-3 fatty acids — fish oil reduces hepatic steatosis in trials but has not consistently shown MASH histology improvement. May be beneficial as part of a broader anti-inflammatory dietary approach.

Complications and Long-Term Prognosis

• Progression to cirrhosis — the most feared outcome; occurs in 15–25% of patients with MASH over 10–20 years. Fibrosis stage at baseline is the strongest predictor.
• Hepatocellular carcinoma (HCC) — MASLD-related HCC is increasing globally as the leading indication for HCC. Unique to MASLD: significant HCC occurs in non-cirrhotic patients (20–50% of cases). Annual HCC surveillance with ultrasound ± AFP is recommended for MASLD cirrhosis patients; guidelines for non-cirrhotic MASH remain controversial.
• Cardiovascular disease — the leading cause of death in MASLD patients (not liver disease). MASLD is an independent risk factor for cardiovascular events beyond traditional Framingham risk factors. Aggressive management of hypertension, dyslipidemia, and diabetes is essential.
• Chronic kidney disease — MASLD is independently associated with CKD progression, likely shared mechanisms (insulin resistance, inflammation, oxidative stress).
• Liver transplantation — MASLD cirrhosis is now the second-leading indication for liver transplantation in the US and is projected to become the first within a decade. Metabolic comorbidities (obesity, diabetes, cardiovascular disease) require careful pretransplant optimization; recurrence of MASLD in the transplanted liver occurs in most patients without lifestyle modification.
• Type 2 diabetes risk — MASLD is a bidirectional risk factor for T2DM; patients with MASLD have 2–5-fold higher risk of developing T2DM, and T2DM markedly accelerates MASLD progression.

Key Research Papers

1. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature (MASLD/MASH). Hepatology. 2023;78(6):1966-1986. PMID: 37363821
2. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease — meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. PMID: 26707365
3. Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis (NASH trial). N Engl J Med. 2021;384(12):1113-1124. PMID: 33185364
4. Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis (MAESTRO-NASH). N Engl J Med. 2024;390(6):497-509. PMID: 38324483
5. Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis (SYNERGY-NASH). N Engl J Med. 2024;391(4):299-310. PMID: 38852958
6. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis (PIVENS). N Engl J Med. 2010;362(18):1675-1685. PMID: 20427778
7. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367-378. PMID: 25865049
8. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection (FIB-4 origin paper). Hepatology. 2006;43(6):1317-1325. PMID: 16729309
9. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357. PMID: 28714183
10. Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547-1554. PMID: 25125077
11. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51(1):121-129. PMID: 19827166
12. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-1402. PMID: 27062661

Back to Table of Contents

Research Papers

Curated PubMed topic searches of peer-reviewed literature on fatty liver disease. Each link opens a live PubMed query so you always see the most current studies.

1. PubMed: MASLD/NAFLD metabolic liver disease
2. PubMed: MASH/NASH treatment fibrosis
3. PubMed: FIB-4 score liver fibrosis
4. PubMed: GLP-1 agonists fatty liver MASH
5. PubMed: Resmetirom THR-beta MASH
6. PubMed: Mediterranean diet NAFLD
7. PubMed: NAFLD HCC non-cirrhotic
8. PubMed: Bariatric surgery NASH fibrosis
9. PubMed: NAFLD cardiovascular mortality
10. PubMed: Insulin resistance hepatic lipogenesis
11. PubMed: Tirzepatide SYNERGY-NASH
12. PubMed: Coffee NAFLD liver fibrosis

Back to Table of Contents

Connections

• Pancreatitis
• Gallbladder Disease
• Gallstones
• Gastritis
• Celiac Disease
• SIBO
• Irritable Bowel Syndrome
• Barrett's Esophagus
• Appendicitis
• Vitamin E
• Zinc
• Choline
• Olive Oil (Mediterranean diet)
• Milk Thistle (silymarin)

Back to Table of Contents

×

Featured Videos